{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 443583795
| IUPAC_name = 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)<br />ethyl]phenol
| image = Desvenlafaxine.svg
| width = 180
| alt = Skeletal formula
| image2 = Desvenlafaxine molecule ball.png
| alt2 = Ball-and-stick model of desvenlafaxine

<!--Clinical data-->
| tradename = Pristiq, Desfax, Ellefore
| Drugs.com = {{drugs.com|monograph|desvenlafaxine-succinate}}
| MedlinePlus = a608022
| licence_US = Desvenlafaxine
| pregnancy_AU = B2
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = 80%
| protein_bound = Low (30%)
| metabolism = CYP3A4, (CYP2D6 is not involved)
| elimination_half-life = 11 h
| excretion = 45% excreted unchanged in urine

<!--Identifiers-->
| IUPHAR_ligand = 7158
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 93413-62-8
| ATC_prefix = N06
| ATC_suffix = AX23
| PubChem = 125017
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06700
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 111300
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = NG99554ANW
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07793
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 83527
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1118

<!--Chemical data-->
| C=16 | H=25 | N=1 | O=2
| molecular_weight = 263.38 g/mol
| smiles = OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = KYYIDSXMWOZKMP-UHFFFAOYSA-N
}}

'''Desvenlafaxine''' ([[brand name]]: '''Pristiq, Desfax, Ellefore'''), also known as '''''O''-desmethylvenlafaxine''', is an [[antidepressant]] of the [[serotonin-norepinephrine reuptake inhibitor]] (SNRI) class developed and marketed by [[Wyeth]] (now part of [[Pfizer]]). Desvenlafaxine is a [[chemical synthesis|synthetic]] [[drug form|form]] of the major active [[metabolite]] of [[venlafaxine]] (sold under the brand names Effexor and Efexor). It is being targeted as the first non-hormonal based treatment for [[menopause]].<ref>{{cite press release |url = http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2007/1185276550318.html |title = Wyeth Receives Approvable Letter From FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated With Menopause |date=2007-07-24 |publisher = [[Wyeth]]| accessdate = 2007-07-31}}</ref>

==Medical uses==
Desvenlafaxine's primary use in medicine is the treatment of [[major depressive disorder]].<ref name = TGA>{{cite web|title=PRODUCT INFORMATION PRISTIQ® desvenlafaxine (as succinate)|work=TGA eBusiness Services|publisher=Pfizer Australia Pty Ltd|date=10 December 2012|accessdate=8 November 2013|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-06360-3|format=PDF}}</ref>

==Adverse effects==
'''<big>Adverse effect incidence</big>'''<ref name = TGA/><ref name = DM>{{cite web|title=DESVENLAFAXINE tablet, extended release [Ranbaxy Pharmaceuticals Inc.]|work=DailyMed|publisher=Ranbaxy Pharmaceuticals Inc.|date=March 2013|accessdate=9 November 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=91cf39c9-4d26-480a-a3a3-a3d8d4c4d222}}</ref><ref>{{cite web|title=desvenlafaxine (Rx) - Pristiq, Khedezla|work=Medscape Reference|publisher=WebMD|accessdate=9 November 2013|url=http://reference.medscape.com/drug/pristiq-khedezla-desvenlafaxine-342964}}</ref>

'''Very common (>10% incidence) adverse effects include:'''
{{colbegin|colwidth=15em}}
*Nausea
*Headache
*Dizziness
*Dry mouth
*[[Hyperhidrosis]]
*Diarrhea
*Insomnia
*Constipation
*Fatigue
{{colend}}

'''Common (1-10% incidence) adverse effects include:'''
{{colbegin|colwidth=15em}}
*Tremor
*Blurred vision
*Mydriasis
*Decreased appetite
*Sexual dysfunction
*Insomnia
*Anxiety
*Elevated cholesterol and triglycerides
*Proteinuria
*Vertigo
*Feeling jittery
*Asthenia
*Nervousness
*Hot flush
*Irritability
*Abnormal dreams
*Urinary hesitation
*Yawning
*Rash
{{colend}}

'''Uncommon (0.1-1% incidence) adverse effects include:'''
{{colbegin|colwidth=15em}}
*Hypersensitivity
*[[Syncope (medicine)|Syncope]]
*Depersonalisation
*[[Hypomania]]
*Withdrawal syndrome
*[[Urinary retention]]
*Epistaxis
*Alopecia (hair loss)
*[[Orthostatic hypotension]]
*Peripheral coldness
{{colend}}

'''Rare (<0.1% incidence) adverse effects include:'''
{{colbegin|colwidth=15em}}
*[[Hyponatraemia]] (low blood sodium)
*Seizures
*Extrapyramidal side effects
*Hallucinations
*[[Angioedema]]
*Photosensitivity reaction
*[[Stevens-Johnson syndrome]]
{{colend}}

'''Unknown frequency adverse effects include:'''
{{colbegin|colwidth=15em}}
*Abnormal bleeding (e.g. gastrointestinal bleeds)
*Narrow-angle [[glaucoma]]
*[[Mania]]
*[[Interstitial lung disease]]
*[[Eosinophilic pneumonia]]
*[[Hypertension]]
*Suicidal behaviour & thoughts
*[[Serotonin syndrome]]
{{colend}}

==Pharmacology==
Desvenlafaxine is a synthetic form of the isolated major active metabolite of [[venlafaxine]], and is categorized as a [[serotonin-norepinephrine reuptake inhibitor]] (SNRI). When most normal metabolizers take venlafaxine, approximately 70% of the dose is metabolized into desvenlafaxine, so the effects of the two drugs are expected to be very similar.<ref name=Foye2012>{{cite book|title=Foye's Principles of Medicinal Chemistry|year=2012|publisher=Lippincott Williams & Wilkins |isbn=978-1-60913-345-0 |page=609|first1=Thomas L.|last1=Lemke |first2=David A. |last2=Williams}}</ref> It works by blocking the [[Monoamine transporter|"reuptake" transporters]] for key [[neurotransmitter]]s affecting mood, thereby leaving more active neurotransmitters in the [[synapse]]. The neurotransmitters affected are [[serotonin]] (5-hydroxytryptamine) and [[norepinephrine]] (noradrenaline). It is approximately 10 times more potent at inhibiting [[serotonin]] uptake than [[norepinephrine]] uptake.<ref>{{cite journal|title=Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor|journal=The Journal of Pharmacology and Experimental Therapeutics|date=August 2006|volume=318|issue=2|pages=657–665|author1=Deecher, DC |author2=Beyer, CE |author3=Johnston, G |author4=Bray, J |author5=Shah, S |author6=Abou-Gharbia, M |author7=Andree, TH |doi=10.1124/jpet.106.103382|pmid=16675639|url=http://jpet.aspetjournals.org/content/318/2/657.full.pdf|format=PDF}}</ref>

{| class="wikitable"
|-
! Transporter !! K<sub>i</sub>[nM]<ref>{{cite web|title=PDSP K<sub>i</sub> Database |work=Psychoactive Drug Screening Program (PDSP) |author1=Roth, BL |author2=Driscol, J |url=http://pdsp.med.unc.edu/pdsp.php |publisher=University of North Carolina at Chapel Hill and the United States National Institute of Mental Health |accessdate=9 November 2013 |date=12 January 2011 |deadurl=yes |archiveurl=https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php |archivedate=8 November 2013 |df= }}</ref>
|-
| [[Serotonin transporter|SERT]] || 61.4
|-
| [[Norepinephrine transporter|NET]] || 2953
|}

==Approval status==

===United States===
[[File:Pristiq pills.jpg|thumb|right|250px|Pristiq 50 mg tablets ([[United States|US]])]]
Wyeth announced on 23 January 2007 that it received an "approvable" letter from the [[Food and Drug Administration]] for desvenlafaxine. Final approval to sell the drug was contingent on a number of things, including:
*A satisfactory FDA inspection of Wyeth's [[Guayama, Puerto Rico]] facility, where the drug is to be manufactured;
*Several [[postmarketing surveillance]] commitments, and follow-up studies on low-dose use, relapse, and use in children;
*Clarity by Wyeth around the company's product education plan for physicians and patients;
*Approval of desvenlafaxine's proprietary name, Pristiq.<ref>{{cite press release |url = http://www.biospace.com/news_story.aspx?StoryID=43424&full=1 |title = Wyeth Receives Approvable Letter From FDA For Pristiq (Desvenlafaxine Succinate) For The Treatment Of Major Depressive Disorder |date = 2007-01-23 |accessdate = 2007-04-04}}</ref>

The FDA approved the drug for antidepressant use in February 2008, and was to be available in US pharmacies in May 2008.<ref>{{cite press release |url = http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/pressreleases/2008/1204331198948.html |title = FDA Approves Pristiq |date=2008-02-29 |publisher = [[Wyeth]] |accessdate = 2008-02-29}}</ref>

In March 2017, the generic form of the drug was made available in the US.

===Canada===
On February 4, 2009, [[Health Canada]] approved use of desvenlafaxine for treatment of depression.<ref>[http://205.193.93.51/NocWeb/viewnoce.jsp?noc=cigci Health Canada Notice of Compliance - Pristiq]. February 4, 2009, retrieved on March 9, 2009.</ref><ref>{{cite web|url=http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2009_pristiq_115439-eng.php|title=Summary Basis of Decision (SBD) <sup>Pr</sup>Pristiq™|date=2009-05-29|publisher=Health Canada|accessdate=2016-12-30}}</ref> Pristiq is now available in Canadian pharmacies.

===European Union===
In 2008, Wyeth withdrew its application for Ellefore, the product under review for treatment of [[major depressive disorder]] in the European Union. In 2012, Pfizer received authorization in Spain to market Pristiq for the disorder in 50&nbsp;mg and 100&nbsp;mg tablets.<ref>{{cite web|url=http://www.aemps.gob.es/cima/especialidad.do?metodo=verPresentaciones&codigo=75561   |title=Pristiq 100 mg Comprimidos de Liberacion Prolongada |publisher=AEMPS Medicines Online Information Center - CIMA |accessdate=2016-12-30}}</ref><ref>{{cite web|url=http://www.aemps.gob.es/cima/especialidad.do?metodo=verPresentaciones&codigo=75560 |title=Pristiq 50 mg Comprimidos de Liberacion Prolongada  |publisher= AEMPS Medicines Online Information Center - CIMA  |accessdate=2016-12-30}} </ref><ref>{{cite web|url=https://www.pfizer.es/sobre_pfizer/medicamentos/pristiq.html|title=Pristiq  |publisher=Pfizer |language=es |accessdate=2016-12-30}}</ref>

=== '''Australia''' ===
Desvenlafaxine is classified as a schedule 4 (prescription only) drug in Australia. It was listed on the [http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2008-11/pbac-psd-desvenlafaxine-nov08 PBS] (Pharmaceutical Benefits Scheme) in 2008 for the treatment of MDD (Major Depressive Disorders).

==Clinical efficacy==
In clinical trials, desvenlafaxine demonstrated a significant superiority to placebo both in changes from baseline in the HAM-D17 score<ref>{{cite journal |vauthors=Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico-Pabia C, Ninan PT |title=An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder |journal=CNS Spectr |volume=14 |issue=3 |pages=144–54 |date=March 2009 |pmid=19407711 |doi= |url=}}</ref> and in measures of well being such as the Sheehan Disability Scale (SDS) and 5-item World Health Organization Well-Being Index (WHO-5).<ref>{{cite journal |vauthors=Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ |title=Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials |journal=J Clin Psychiatry |volume=70 |issue=10 |pages=1365–71 |date=October 2009 |pmid=19906341 |doi=10.4088/JCP.09m05133blu |url=}}</ref>

==See also==
* [[Ansofaxine]]

==References==
{{Reflist|2}}

==External links==
* [http://www.pristiq.com/ Pfizer's Pristiq site for U.S. residents]

{{Antidepressants}}
{{Monoamine reuptake inhibitors}}
{{Phenethylamines}}

[[Category:Cyclohexanols]]
[[Category:Phenethylamines]]
[[Category:Phenols]]
[[Category:Serotonin-norepinephrine reuptake inhibitors]]
[[Category:Tertiary alcohols]]
[[Category:Human drug metabolites]]